Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient

26 Apr 2021

Abstract excerpt

To the Editor—Kumar et al [1] reported on the role of single bamlanivimab in preventing hospitalization associated with coronavirus disease 2019 (COVID-19). There is scarce evidence of prevalence of emergent variants in patients treated with bamlanivimab [2]. But very little is known about treatment-emergent variants in the B.1.1.7 lineage, which is by now the dominant strain throughout Europe and North America....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Cell Function and Interaction
Share to Immunodeficiency and Autoimmune Disorders
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34009286
DOI: 10.1093/cid/ciab392

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed PatientPMID 34009286Read ↗

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in GermanySemantic proximity Read ↗

Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.Semantic proximity Read ↗

Variant-specific humoral immune response to SARS-CoV-2 escape mutants arising in clinically severe, prolonged infectionSemantic proximity Read ↗

Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient.Semantic proximity Read ↗

Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.Semantic proximity Read ↗

Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection.Semantic proximity Read ↗

SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody MonotherapySemantic proximity Read ↗

Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.